Global Apomorphine Hydrochloride Injection Sales Market Report 2021

Apomorphine is a non-selective dopamine agonist which activates both D2-like and, to a much lesser extent, D1-like receptors. It also acts as an antagonist of 5-HT2 and α-adrenergic receptors with high affinity. The compound is historically a morphine decomposition product made by boiling morphine with concentrated acid, hence the -morphine suffix. Apomorphine does not actually contain morphine or its skeleton, nor does it bind to opioid receptors.

Market Analysis and Insights: Global Apomorphine Hydrochloride Injection Market
The global Apomorphine Hydrochloride Injection market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Apomorphine Hydrochloride Injection Scope and Market Size
The global Apomorphine Hydrochloride Injection market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Apomorphine Hydrochloride Injection market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Pen Injectors
Infusion Pumps

Segment by Application
Parkinson Disease
Erectile Dysfunction

The Apomorphine Hydrochloride Injection market is analysed and market size information is provided by regions (countries). Segment by Application, the Apomorphine Hydrochloride Injection market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Supernus Pharmaceuticals
Britannia Pharmaceuticals STADA
Ever Pharma
Evolan Pharma AB (PharmSwed)